Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

37 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Randomized study comparing full dose monotherapy (S-1 followed by irinotecan) and reduced dose combination therapy (S-1/oxaliplatin followed by S-1/irinotecan) as initial therapy for older patients with metastatic colorectal cancer: NORDIC 9.
Winther SB, Österlund P, Berglund Å, Glimelius B, Qvortrup C, Sorbye H, Pfeiffer P; - on behalf of the Academy of Geriatric Cancer Research (AgeCare). Winther SB, et al. BMC Cancer. 2017 Aug 16;17(1):548. doi: 10.1186/s12885-017-3526-8. BMC Cancer. 2017. PMID: 28814275 Free PMC article. Clinical Trial.
Reduced-dose combination chemotherapy (S-1 plus oxaliplatin) versus full-dose monotherapy (S-1) in older vulnerable patients with metastatic colorectal cancer (NORDIC9): a randomised, open-label phase 2 trial.
Winther SB, Liposits G, Skuladottir H, Hofsli E, Shah CH, Poulsen LØ, Ryg J, Osterlund P, Berglund Å, Qvortrup C, Glimelius B, Sorbye H, Pfeiffer P. Winther SB, et al. Lancet Gastroenterol Hepatol. 2019 May;4(5):376-388. doi: 10.1016/S2468-1253(19)30041-X. Epub 2019 Mar 7. Lancet Gastroenterol Hepatol. 2019. PMID: 30852136 Clinical Trial.
TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial.
Pfeiffer P, Yilmaz M, Möller S, Zitnjak D, Krogh M, Petersen LN, Poulsen LØ, Winther SB, Thomsen KG, Qvortrup C. Pfeiffer P, et al. Among authors: winther sb. Lancet Oncol. 2020 Mar;21(3):412-420. doi: 10.1016/S1470-2045(19)30827-7. Epub 2020 Jan 27. Lancet Oncol. 2020. PMID: 31999946 Clinical Trial.
Frailty screening for predicting rapid functional decline, rapid progressive disease, and shorter overall survival in older patients with gastrointestinal cancer receiving palliative chemotherapy - a prospective, clinical study.
Jespersen E, Winther SB, Minet LR, Möller S, Pfeiffer P. Jespersen E, et al. Among authors: winther sb. J Geriatr Oncol. 2021 May;12(4):578-584. doi: 10.1016/j.jgo.2020.10.007. Epub 2020 Oct 21. J Geriatr Oncol. 2021. PMID: 33830020
Quality of Life in Vulnerable Older Patients with Metastatic Colorectal Cancer Receiving Palliative Chemotherapy-The Randomized NORDIC9-Study.
Liposits G, Eshøj HR, Möller S, Winther SB, Skuladottir H, Ryg J, Hofsli E, Shah CH, Poulsen LØ, Berglund Å, Qvortrup C, Österlund P, Glimelius B, Sorbye H, Pfeiffer P. Liposits G, et al. Among authors: winther sb. Cancers (Basel). 2021 May 26;13(11):2604. doi: 10.3390/cancers13112604. Cancers (Basel). 2021. PMID: 34073363 Free PMC article.
37 results